12
SEP
2023
Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company’s Scientific Advisory Board
Comments : Off
BETHESDA, MD, September 12, 2023 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announces that Dr. Linda Liau, MD, PhD, MBA has joined the Company’s Scientific Advisory Board (SAB). Dr. Liau served as the Principal Investigator of the Phase 3 trial of DCVax®-L for treatment of glioblastoma. She is Chair of the Department of Neurosurgery at... Read More